

Diseases of the respiratory tract with the formation of viscous sputum (in complex therapy).
Excipients: microcrystalline cellulose - 13 mg, povidone (K-30) - 8 mg, magnesium stearate - 3 mg.
Hard gelatin capsules: the body and cap of the capsule - titanium dioxide - 1.3333%, the quinoline yellow dye - 0.9197%, the sunset sunset sunflower yellow - 0.0044%, gelatin - up to 100%.
No customer reviews for the moment.
1 capsule (300 mg), 2 times a day.
If there is no improvement within 5 days after the start of the use of the drug or if there is a deterioration, you should contact your doctor.
The incidence of adverse reactions is according to the WHO classification: very often (≥1 / 10 cases), often (≥1 / 100 and <1/10 cases), infrequently (≥1 / 1000 and <1/100 cases), rarely (≥ 1/10000 and <1/1000 cases) and very rarely (<1/10000 cases), the frequency is unknown.
From the gastrointestinal tract: rarely - heartburn, nausea, diarrhea; very rarely, nausea, epigastric pain, loss or change in taste sensitivity at the beginning of treatment.
On the part of the skin and subcutaneous tissues: rarely - allergic reactions: redness of the skin, edema, eczema; angioedema.
Violations of the respiratory system, chest and mediastinum; very rarely - shortness of breath.
Hypersensitivity to the components that make up the drug.
Children's age up to 18 years.
Liver dysfunction.
Renal failure.
Homocysteinuria (the drug is a source of homocysteine, therefore, disorders of amino acid metabolism are possible in patients on a diet with a reduced content of free methionine).
Pregnancy (I trimester).
Breastfeeding period.
Carefully
The drug should be prescribed with caution to patients with marked violations of the liver; with diseases of the bronchi, accompanied by excessive accumulation of secretions.
With simultaneous use of erdostein increases the concentration of amoxicillin in the bronchial secretion, which allows for a faster response to therapy compared to amoxicillin monotherapy.
During treatment it is necessary to take a sufficient amount of liquid, which increases the expectorant effect. In cases of impaired motility of the bronchi or with a significant amount of sputum, the use of the drug requires caution, due to the risk of delayed discharge in the respiratory tract and an increased risk of attaching infection or bronchospasm.
Influence on ability to steer vehicles, mechanisms
It does not affect the ability to drive vehicles, mechanisms and engage in other activities that require increased concentration of attention and psychomotor speed.
No cases of overdose have been reported. However, in cases of overdose or in case of accidental use by children, gastric lavage and symptomatic therapy are recommended.
Studies and clinical trials of Erdosteine (Click to expand)